|

MK-4830 Clinical Trials

2 actively recruiting trials across 2 locations

▼ -1 trial since May 2026

Also known as: anti-immunoglobulin-like transcript 4 (anti-ILT4)

Pipeline

Phase 1/2: 2

Top Sponsors

  • Merck Sharp & Dohme LLC2

Indications

  • Cancer2
  • Esophageal Squamous Cell Carcinoma1
  • Carcinoma, Non-Small-Cell Lung1
  • Lung Cancer1

Gilbert, Arizona1 trial

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Banner MD Anderson Cancer Center ( Site 0001)

Phase 1/2

Tucson, Arizona1 trial

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.